Bionano Genomics, Inc.(BNGO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,887 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
BNGO Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Bionano Genomics, Inc. (BNGO), a Technology sector company. 13F Pro's AI-powered ranking engine scores BNGO at 12.6/100 on a 32-signal composite quality model, placing it at rank #2,887 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (3.3) and revenue scale (5.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Bionano Genomics, Inc. reports quarterly revenue of $8.2M, net income of $-7.4M, an operating margin of -88.3%. Top institutional holders of BNGO by reported 13-F value include GSA CAPITAL PARTNERS LLP, CARRET ASSET MANAGEMENT, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. BNGO trades on the Nasdaq exchange and files with the SEC under CIK 1411690. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BNGO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bionano Genomics, Inc. directly from SEC EDGAR. Bionano Genomics, Inc.'s 13F Pro composite quality score has ranged between 9 and 28 since 2022, currently 12.6 — a declining long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$8.2M
Net Income
Q2 2026
$-7.4M
Operating Margin
Q2 2026
-88.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-7.4% YoYNet Income
+76.4% YoYOperating Income
+67.9% YoYEPS (Diluted)
+94.5% YoYTotal Assets
-4.0% YoYTotal Debt
Op. Cash Flow
+76.3% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $28.5M -7.4% | $30.8M -14.8% | $36.1M +29.9% | $27.8M +54.6% | $18.0M +111.5% | $8.5M |
| Net Income | $-26.4M +76.4% | $-112.0M +51.8% | $-232.5M -75.3% | $-132.6M -83.1% | $-72.4M -76.2% | $-41.1M |
| Operating Income | $-33.3M +67.9% | $-104.0M +51.7% | $-215.2M -63.4% | $-131.7M -70.8% | $-77.1M -100.0% | $-38.6M |
| EPS (Diluted) | $-4.85 +94.5% | $-88.13 +78.4% | $-408.60 -8821.4% | $-4.58 -1661.5% | $-0.26 | — |
| Total Assets | $73.6M -4.0% | $76.7M -64.2% | $214.4M -30.3% | $307.5M -18.5% | $377.1M +523.8% | $60.5M |
| Total Debt | — | — | — | — | $0.00 -100.0% | $16.3M |
| Operating Cash Flow | $-16.3M +76.3% | $-68.9M +44.9% | $-125.2M -0.3% | $-124.8M -73.5% | $-71.9M -87.7% | $-38.3M |
| Free Cash Flow | — | — | — | — | — | $-38.3M |
Get alerted when BNGO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Bionano Genomics, Inc. including:
Top Institutional Holders of BNGO
GSA CAPITAL PARTNERS LLP
$170.0K150,284 shCARRET ASSET MANAGEMENT, LLC
$141.3K125,000 shGEODE CAPITAL MANAGEMENT, LLC
$101.7K89,993 shVANGUARD CAPITAL MANAGEMENT LLC
$93.1K82,388 shVANGUARD FIDUCIARY TRUST CO
$58.3K51,578 shRENAISSANCE TECHNOLOGIES LLC
$57.7K51,100 shJANE STREET GROUP, LLC
$40.4K35,728 shPRUDENTIAL FINANCIAL INC
$35.7K31,600 shNORTHERN TRUST CORP
$27.8K24,561 shXTX Topco Ltd
$18.4K16,295 sh
| Fund | Value | Shares |
|---|---|---|
| GSA CAPITAL PARTNERS LLP | $170.0K | 150,284 |
| CARRET ASSET MANAGEMENT, LLC | $141.3K | 125,000 |
| GEODE CAPITAL MANAGEMENT, LLC | $101.7K | 89,993 |
| VANGUARD CAPITAL MANAGEMENT LLC | $93.1K | 82,388 |
| VANGUARD FIDUCIARY TRUST CO | $58.3K | 51,578 |
| RENAISSANCE TECHNOLOGIES LLC | $57.7K | 51,100 |
| JANE STREET GROUP, LLC | $40.4K | 35,728 |
| PRUDENTIAL FINANCIAL INC | $35.7K | 31,600 |
| NORTHERN TRUST CORP | $27.8K | 24,561 |
| XTX Topco Ltd | $18.4K | 16,295 |
Companies Similar to BNGO
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Flux Power Holdings, Inc.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Veritone, Inc.
Identiv, Inc.
Digimarc CORP
Phunware, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Technology Companies
View all Technology →Put BNGO on your watchlist
Track score changes the day Bionano Genomics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BNGO a good stock to buy?
13F Pro's AI-powered analysis of Bionano Genomics, Inc. (BNGO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BNGO are available on the BNGO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BNGO is classified as a small company.
Which hedge funds own BNGO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BNGO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Bionano Genomics, Inc.'s investment landscape.